26 jul: Torsdagens aktier: Forsvarstale gav festfyrværkeri
27 jul: USA/aktier: Wall Street dansede efter Draghis pibe
26-07-2012 22:51:00

Amgen 2nd-Quarter Profit Rises 8.2%; 2012 Outlook Raised

Relateret indhold

By Tess Stynes

Amgen Inc.'s (AMGN) second-quarter earnings rose 8.2% as weaker sales of the biopharmaceutical company's anemia drugs were offset by growth of other treatments.

Shares rose 4.7% to $83 in after-hours trading Thursday as adjusted earnings and revenue beat expectations and the company raised its 2012 outlook. Through the close, the stock was up about 23% this year.

For the year, the company raised its per-share earnings estimate to a range of $6.20 to $6.35 on revenue of $16.9 billion to $17.2 billion, from its prior estimates for $5.90 to $6.15 and $16.1 billion to $16.5 billion.

Amgen has been pursuing deals to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed a $1.16 billion acquisition of Micromet Inc., a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.27 billion, or $1.61 a share, up from $1.17 billion, or $1.25 a share, a year earlier. Excluding acquisition-related charges, stock-compensation expenses and other items, earnings were up at $1.83 from $1.37.

Revenue increased 13% to $4.48 billion, including 8% growth in product sales.

Analysts polled by Thomson Reuters most recently projected earnings of $1.54 a share on revenue of $4.08 billion.

Combined sales of Neulasta and Neupogen, which are used to ward off infections in patients undergoing cancer treatment, grew 2% mainly on an increase in U.S. average selling prices. Enbrel sales jumped 11%.

However, sales of anti-anemia drugs Aranesp and Epogen were down about 8% and 3%, respectively.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Second-quarter sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, saw sales increase 17% from the first quarter. Sales of Prolia, for osteoporosis in women, climbed 36% quarter to quarter.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 26, 2012 16:51 ET (20:51 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Glunz FY: Ingen udbytte i vente efter ventet underskud

25-08-2016 15:09:39
Der var underskud på bundlinjen for Glunz & Jensen, der blandt andet laver og sælger udstyr til trykkerier, i det netop overståede regnskabsår, der løb fra 1. j..

Alm. Brand/CEO: Tre årsager til samlet opjustering

25-08-2016 13:00:16
Alm. Brand-koncernen kunne i torsdag morgens regnskab for andet kvartal opjustere forventningerne til hele årets resultat før skat med 100 mio. kr.Langt største..

ATP/CEO: Dong Energy skæppede med 2,9 mia. kr. - NY

25-08-2016 11:06:43
Pensionsgiganten ATP fik i første halvår et investeringsafkast på 6,7 pct. svarende til 6,9 mia. kr. Mens man tabte på udenlandske aktier - de japanske især - s..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Zealand H1: Venter bedste år nogensinde med bredere portefølje
2
Aktier/tendens: Strøm af regnskaber ventes at dominere
3
Parken/Nordnet: Aktien kan stige tocifret efter opjustering
4
Torsdagens aktier: Pandora på pinebænken efter USA-skuffelse
5
Aktier/middag: Regnskabsvrimmel med plus til Sydbank

Relaterede aktiekurser

Amgen Inc 170,12 -0,4% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. august 2016 20:25:19
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160823.1 - EUROWEB3 - 2016-08-25 20:25:19 - 2016-08-25 20:25:19 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x